Watch our webinar with Immuron, featuring CEO Steven Lydeamore. An interview followed by live Q&A with the audience.
Immuron Limited (ASX:IMC | NASDAQ:IMRN) is a biopharmaceutical company redefining how we treat and prevent gut-mediated and infectious diseases. Using targeted, orally delivered antibodies, Immuron offers scalable, clinically backed solutions for global health challenges — starting with one of the most common travel-related illnesses, traveller's diarrhea
Management tells one side of the story. Sharewise clients get independent research and Advisor access across ASX, US and global markets.